Adam Vogel, PhD, Professor of Speech Neuroscience at The University of Melbourne and Chief Science Officer at Redenlab, discusses the emerging role of speech analytics as an objective, scalable biomarker in neurodegenerative disease research.
Adam Vogel, PhD
Advertisement
Articles by Adam Vogel, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Former NFL Running Back Chris Johnson Diagnosed With ALS at 40
2
FDA Accepts Sarepta's sNDAs for Casimersen and Golodirsen for Duchenne Muscular Dystrophy
3
Long-Term Efficacy of Anti-CD20 Therapies in MS: What the Evidence Shows
4
FDA Aligns With Cognition Therapeutics on Phase 3 Trial Design for Zervimesine in DLB-Associated Psychosis
5